13.35
price down icon1.11%   -0.15
after-market アフターアワーズ: 13.35
loading

Mineralys Therapeutics Inc (MLYS) 最新ニュース

pulisher
Apr 18, 2025

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week - MSN

Apr 18, 2025
pulisher
Apr 16, 2025

Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 By Investing.com - Investing.com Canada

Apr 16, 2025
pulisher
Apr 15, 2025

Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Mineralys Therapeutics chief medical officer sells $165,185 in stock - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Mineralys Therapeutics CFO Adam Levy sells $129,684 in stock By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Mineralys Therapeutics Executives Sell Shares - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Mineralys therapeutics CEO Jon Congleton sells shares worth $186,802 - Investing.com

Apr 15, 2025
pulisher
Apr 12, 2025

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance

Apr 12, 2025
pulisher
Apr 09, 2025

SEC Form DEF 14A filed by Mineralys Therapeutics Inc. - Quantisnow

Apr 09, 2025
pulisher
Apr 09, 2025

SEC Form DEFA14A filed by Mineralys Therapeutics Inc. - Quantisnow

Apr 09, 2025
pulisher
Apr 07, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 07, 2025
pulisher
Apr 03, 2025

Mineralys Therapeutics CMO Rodman sells shares worth $879,008 - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Mineralys Therapeutics CMO Rodman sells shares worth $879,008 By Investing.com - Investing.com Canada

Apr 03, 2025
pulisher
Apr 02, 2025

Buy Rating Affirmed for Lorundrostat Amid Positive Trial Results and Market Potential - TipRanks

Apr 02, 2025
pulisher
Apr 01, 2025

When (MLYS) Moves Investors should Listen - news.stocktradersdaily.com

Apr 01, 2025
pulisher
Apr 01, 2025

Stifel maintains Buy on Mineralys stock with $45 target - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

ACC25: Mineralys' uncontrolled hypertension drug aces trial - Pharmaphorum

Apr 01, 2025
pulisher
Mar 31, 2025

Stifel maintains Buy on Mineralys stock with $45 target By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks

Mar 31, 2025
pulisher
Mar 30, 2025

Mineralys Therapeutics presents results from Phase 2 Advance-HTN trial - TipRanks

Mar 30, 2025
pulisher
Mar 30, 2025

Promising Clinical Trial Results and Safety Profile of Lorundrostat Support Buy Rating for Mineralys Therapeutics - TipRanks

Mar 30, 2025
pulisher
Mar 30, 2025

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - The Manila Times

Mar 30, 2025
pulisher
Mar 29, 2025

Mineralys Therapeutics Announces Late-Breaking Data from - GlobeNewswire

Mar 29, 2025
pulisher
Mar 29, 2025

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25) - TradingView

Mar 29, 2025
pulisher
Mar 29, 2025

Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan

Mar 29, 2025
pulisher
Mar 28, 2025

Mineralys Therapeutics, Inc. Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25) - Marketscreener.com

Mar 28, 2025
pulisher
Mar 27, 2025

Mineralys Therapeutics to Host Webinar on Lorundsrostat and Hypertension Treatment Progress - MSN

Mar 27, 2025
pulisher
Mar 26, 2025

3 Brilliant Space Stocks to Buy Now and Hold for the Long Term - The Globe and Mail

Mar 26, 2025
pulisher
Mar 26, 2025

Insiders Make Huge Purchases of These 4 Biotech Stocks - 24/7 Wall St.

Mar 26, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Insider Monkey

Mar 25, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics to Host KOL Call to Discuss Clinical - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics to Host Conference Call on Advance-HTN and Launch-HTN Clinical Trial Results Featuring Dr. Luke Laffin - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

Groundbreaking Hypertension Treatment Data: Cleveland Clinic Expert Reveals Pivotal Trial Results - Stock Titan

Mar 25, 2025
pulisher
Mar 24, 2025

MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

Mar 24, 2025
pulisher
Mar 21, 2025

RA CAPITAL MANAGEMENT, L.P. Increases Stake in Mineralys Therape - GuruFocus

Mar 21, 2025
pulisher
Mar 20, 2025

Lorundrostat Shows Promise in Treatment of Uncontrolled and Resistant Hypertension in trials - Medical Dialogues

Mar 20, 2025
pulisher
Mar 20, 2025

Buy Rating Justified for Mineralys Therapeutics, Inc. Due to Promising Study Results and Manageable Safety Profile - TipRanks

Mar 20, 2025
pulisher
Mar 19, 2025

Mineralys Therapeutics to Present Phase 2 Advance-HTN Trial Data at ACC.25 - MSN

Mar 19, 2025
pulisher
Mar 19, 2025

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - The Manila Times

Mar 19, 2025
pulisher
Mar 18, 2025

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics Announces Closing of Underwriters’ - GlobeNewswire

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

10 Pump and Dump Stocks Favored by Hedge Funds - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

Mineralys to present hypertension drug trial results at ACC.25 By Investing.com - Investing.com Australia

Mar 18, 2025
$20.04
price up icon 2.51%
$72.65
price up icon 3.49%
$32.60
price up icon 1.27%
$24.61
price up icon 6.77%
$98.76
price up icon 0.52%
biotechnology ONC
$230.98
price up icon 1.24%
大文字化:     |  ボリューム (24 時間):